PL1954699T3 - Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR - Google Patents

Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR

Info

Publication number
PL1954699T3
PL1954699T3 PL06808609T PL06808609T PL1954699T3 PL 1954699 T3 PL1954699 T3 PL 1954699T3 PL 06808609 T PL06808609 T PL 06808609T PL 06808609 T PL06808609 T PL 06808609T PL 1954699 T3 PL1954699 T3 PL 1954699T3
Authority
PL
Poland
Prior art keywords
pyrazo
pyrido
mtor inhibitors
pyrimidopyrimidine derivatives
pyrimidopyrimidine
Prior art date
Application number
PL06808609T
Other languages
English (en)
Polish (pl)
Inventor
Marc Geoffrey Hummersone
Sylvie Gomez
Keith Allan Menear
Graeme Cameron Murray Smith
Karine Malagu
Heather Mary Ellen Duggan
Xiao-Ling Fan Cockcroft
Gesine Johanna Hermann
Original Assignee
Kudos Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37533284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1954699(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0524047A external-priority patent/GB0524047D0/en
Application filed by Kudos Pharm Ltd filed Critical Kudos Pharm Ltd
Publication of PL1954699T3 publication Critical patent/PL1954699T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL06808609T 2005-11-22 2006-11-20 Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR PL1954699T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US73890205P 2005-11-22 2005-11-22
GB0524047A GB0524047D0 (en) 2005-11-25 2005-11-25 Compounds
US82330906P 2006-08-23 2006-08-23
US82330806P 2006-08-23 2006-08-23
EP06808609A EP1954699B1 (en) 2005-11-22 2006-11-20 PYRIDO-, PYRAZO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
PCT/GB2006/004327 WO2007060404A1 (en) 2005-11-22 2006-11-20 PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS

Publications (1)

Publication Number Publication Date
PL1954699T3 true PL1954699T3 (pl) 2013-01-31

Family

ID=37533284

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06808609T PL1954699T3 (pl) 2005-11-22 2006-11-20 Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR

Country Status (15)

Country Link
US (1) US20080194546A1 (enExample)
EP (1) EP1954699B1 (enExample)
JP (1) JP5161102B2 (enExample)
KR (1) KR101464384B1 (enExample)
AR (1) AR057626A1 (enExample)
AU (1) AU2006318948B2 (enExample)
CA (1) CA2628920C (enExample)
EC (1) ECSP088536A (enExample)
HR (1) HRP20120963T1 (enExample)
IL (1) IL191196A (enExample)
NO (1) NO341055B1 (enExample)
PL (1) PL1954699T3 (enExample)
TW (1) TWI452047B (enExample)
UY (1) UY29938A1 (enExample)
WO (1) WO2007060404A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2378473T3 (es) * 2005-12-21 2012-04-12 Abbott Laboratories Compuestos antivirales
EP1971611B1 (en) 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
CN101558067B (zh) * 2006-08-23 2014-05-28 库多斯药物有限公司 作为mtor抑制剂的2-甲基吗啉吡啶并、吡唑并和嘧啶并-嘧啶衍生物
HUE033894T2 (en) * 2006-08-23 2018-01-29 Kudos Pharm Ltd 2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
WO2009039140A1 (en) * 2007-09-17 2009-03-26 Smithkline Beecham Corporation Pyridopyrimidine derivatives as pi3 kinase inhibitors
MX2010004074A (es) * 2007-10-15 2010-07-02 Astrazeneca Ab Combinacion 059.
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2262504A1 (en) * 2008-02-21 2010-12-22 AstraZeneca AB Combination therapy 238
UY31917A (es) * 2008-06-20 2010-01-29 Astrazeneca Ab Compuestos de pirido-pirimidina inhibidores de mtor, composiciones farmaceuticas que los comprenden, procesos para su preparación y su uso como medicamento.
CA2729045A1 (en) * 2008-07-31 2010-02-04 Philippe Bergeron Pyrimidine compounds, compositions and methods of use
JP2012506898A (ja) * 2008-10-31 2012-03-22 ノバルティス アーゲー ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AU2010322114B2 (en) 2009-11-18 2014-07-31 Novartis Ag Methods and compositions for treating solid tumors and other malignancies
WO2011067356A2 (en) 2009-12-03 2011-06-09 Novartis Ag Polymorphs of a mek inhibitor
WO2011067348A2 (en) 2009-12-03 2011-06-09 Novartis Ag Mek inhibitor salts and solvates thereof
EP2992878A1 (en) 2010-02-03 2016-03-09 Signal Pharmaceuticals, LLC Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
EP2539337A1 (en) * 2010-02-22 2013-01-02 F. Hoffmann-La Roche AG Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
WO2011120911A1 (en) 2010-03-30 2011-10-06 Novartis Ag Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
EP3235818A3 (en) 2010-04-01 2018-03-14 Critical Outcome Technologies, Inc. Compounds for the treatment of hiv
ES2689177T3 (es) 2010-04-13 2018-11-08 Novartis Ag Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
KR20130048293A (ko) 2010-06-25 2013-05-09 노파르티스 아게 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
WO2012099581A1 (en) 2011-01-19 2012-07-26 Takeda Pharmaceutical Company Limited Dihydrofuropyrimidine compounds
AU2012290056B2 (en) 2011-08-03 2015-03-19 Signal Pharmaceuticals, Llc Identification of gene expression profile as a predictive biomarker for LKB1 status
CN102911172A (zh) * 2011-08-04 2013-02-06 上海恒瑞医药有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途
CN103374021B (zh) * 2012-04-21 2015-10-28 通化济达医药有限公司 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
ES2821102T3 (es) 2012-11-29 2021-04-23 Merck Patent Gmbh Derivados de azaquinazolincarboxamida
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
EA030808B1 (ru) 2013-04-17 2018-09-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ
HK1221174A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法
MX364101B (es) 2013-04-17 2019-04-12 Signal Pharm Llc Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata.
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
WO2014172432A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
CA3143529A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
WO2018144791A1 (en) * 2017-02-03 2018-08-09 Millennium Pharmaceuticals, Inc. Combination of vps34 inhibitors and mtor inhibitors
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
RU2771201C2 (ru) * 2017-11-06 2022-04-28 Медшайн Дискавери Инк. ПИРИДОПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ВЫПОЛНЯЮЩИЕ ФУНКЦИЮ ДВОЙНЫХ ИНГИБИТОРОВ mTORC 1/2
WO2021133509A1 (en) * 2019-12-27 2021-07-01 Angex Pharmaceutical, Inc. Heterocyclic compounds as mtor inhibitors
CA3167339A1 (en) 2020-01-13 2021-07-22 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
EP4161926A4 (en) * 2020-06-03 2024-06-19 Yumanity Therapeutics, Inc. PYRIDOPYRIMIDINES AND THEIR METHODS OF USE
WO2022042630A1 (en) * 2020-08-26 2022-03-03 InventisBio Co., Ltd. Heteroaryl compounds, preparation methods and uses thereof
CN117088898A (zh) * 2022-05-13 2023-11-21 中国药科大学 稠环嘧啶类化合物及其制备方法、药物组合物和应用
WO2024057013A1 (en) * 2022-09-12 2024-03-21 Exscientia Ai Limited Nlrp3 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) * 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US4560685A (en) * 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) * 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
ATE321029T1 (de) * 1999-09-07 2006-04-15 Syngenta Participations Ag Neue herbizide
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
GB0428475D0 (en) * 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders

Also Published As

Publication number Publication date
IL191196A (en) 2016-02-29
ECSP088536A (es) 2008-07-30
JP2009516727A (ja) 2009-04-23
TW200738706A (en) 2007-10-16
JP5161102B2 (ja) 2013-03-13
HK1124039A1 (en) 2009-07-03
CA2628920C (en) 2015-12-29
KR101464384B1 (ko) 2014-11-21
KR20080070079A (ko) 2008-07-29
EP1954699B1 (en) 2012-09-19
WO2007060404A1 (en) 2007-05-31
US20080194546A1 (en) 2008-08-14
TWI452047B (zh) 2014-09-11
AU2006318948A1 (en) 2007-05-31
CA2628920A1 (en) 2007-05-31
UY29938A1 (es) 2007-06-29
NO20082101L (no) 2008-08-15
HRP20120963T1 (hr) 2012-12-31
AU2006318948B2 (en) 2011-02-24
AR057626A1 (es) 2007-12-05
NO341055B1 (no) 2017-08-14
EP1954699A1 (en) 2008-08-13

Similar Documents

Publication Publication Date Title
PL1954699T3 (pl) Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
ZA200806148B (en) 2-adamantylurea derivatives as selective 11ß-HSD1 inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
PL2057156T3 (pl) Pochodne 2-metylomorfolinowe pirydo-, pirazo- i pirymido-pirymidyny jako inhibitory mTOR
IL184674A0 (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EP1878727A4 (en) 2-AMINOQUINAZOLINE DERIVATIVES
GB0518783D0 (en) Indolizine compounds
IL192092A0 (en) Aryl-isoxazolo-4-yl-oxadiazole derivatives
ZA200707358B (en) 1-benzylindole-2-carboxamide derivatives
HUS2000022I1 (hu) Tiglien-3-on származékok
ZA200802421B (en) 1-Acyldihydropyrazol derivatives
ZA200804257B (en) Azaindole-2-carboxamide derivatives
ZA200805353B (en) Aryl-isoxazol-4-yl-imidazole derivatives
PL1954674T3 (pl) Nowe pochodne N-fenetylokarboksyamidu
ZA200900992B (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
IL191138A0 (en) Pyrazoloisoquinoline derivatives
ZA200800672B (en) Introcatechol derivatives as COMT inhibitors
ZA200804104B (en) Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
ZA200802989B (en) Naphthyridin derivatives
ZA200705383B (en) Benzoyl-tetrahydropyridine as GlyT-1 inhibitors
GB0511410D0 (en) Benzotrizepinone derivatives
SI1954699T1 (sl) Derivati pirido-, pirazo in pirimidopirimidina kot inhibitorji mTOR
GB0516967D0 (en) Inhibitors